PTPRC: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of PTPRC. The page also collects GeneMedi's different modalities and formats products for PTPRC in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the PTPRC target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitosis, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus is classified as a receptor type PTP. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. [provided by RefSeq, Jun 2012]
|Gene Official Name||PTPRC|
|Gene Alias||B220, CD45, CD45R, GP180, L-CA, LCA, LY5, T200|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index|
Pre-made PTPRC-specific INN-index biosimilar (antibody&conjugates)-Apamistamab, iodine (131I) apamistamab
Anti-PTPRC therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-ab-029||Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody||Apamistamab||PTPRC||Whole mAb Radiolabelled|
|GMP-Bios-INN-875||Pre-Made Iodine (131I) Apamistamab Biosimilar, Radiolabelled Antibody, Anti-Ptprc Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody||iodine (131I) apamistamab||PTPRC||Radiolabelled antibody|
Pre-made anti-PTPRC inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-PTPRC benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-PTPRC mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T43115-Ab||Anti-PTPRC monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|